Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lot-to-lot Consistency of Hecolin Hepatitis E Vaccine
NCT03365921Phase 4Completed
- Sponsor
- Xiamen Innovax Biotech Co., Ltd.
- Start
- Oct 2018
- Primary completion
- Jun 2019
- Modality
- Recombinant Protein Vaccines
- Countries
- 1
01
Overview
A Phase 4 trial of HEV 239 in hepatitis E (HEV), sponsored by Xiamen Innovax Biotech Co., Ltd.. Started Oct 2018; status: completed.
02
Drugs
HEV 239
03
Conditions
hepatitis E (HEV)
Beyond the preview
Go deeper on NCT03365921.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03365921.